P&G licenses reflux drug

Procter & Gamble in-licensed a drug for treating gastrointestinal disorders, the first since its license-and-acquisitions business model took effect earlier this year. Under the deal, P&G will make an upfront payment of $25 million to the compound’s developer, ARYx Therapeutics. Payments could reach $435 million over the life of the project, including $250 million before the drug—dubbed ATI-7505—is sold. The drug is in phase II clinical trials. P&G once sold another heartburn drug, blockbuster Propulsid (cisapride), but withdrew it in 2000 due to concerns over possible heart problems. ATI-7505, the firms say, was designed to retain Propulsid’s mechanism of action but without side effects. The licensing deal with ARYx is the first since P&G announced in February it had decided to acquire new prescription drugs rather than invent them internally. P&G is honing in on three areas: musculoskeletal, women’s health and gastrointestinal. Drugs it sells in those areas are Actonel for osteoporosis, Enablex for postmenopausal conditions and Asacol for ulcerative colitis.
You must be a registered member of MMM to post a comment.

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.